Outcomes and side effects after first-line treatment with combination therapies for kidney cancer
This report looked at the results from 4 studies comparing [...]
Stereotactic radiotherapy with immunotherapy or targeted therapy for metastatic kidney cancer
This study looked at the safety and effectiveness of targeted [...]
ARO-HIF2 shows promise for advanced kidney cancer
A small phase 1b study of a new medicine called [...]
Lenvatinib plus pembrolizumab in for untreated and previously treated metastatic kidney cancer
Results from a phase Ib/II study looking at lenvatinib plus [...]
ASCO GU 2021: Combination of HIF-2α inhibitor and cabozantinib is active in previously treated advanced kidney cancer
In a small phase 2 study presented at the virtual [...]
Safety and efficacy of TiNivo in patients with metastatic kidney cancer
Tivozanib is a drug that blocks the blood supply to [...]
Safety and efficacy of nivolumab for non-clear cell kidney cancer
Nivolumab alone and in combination with ipilimumab is used for the treatment of [...]
Safety and efficacy of immunotherapy rechallenge in patients with kidney cancer
There are a number of immune checkpoint inhibitor drugs available [...]
ASCO 2020: HIF-2 alpha inhibitor induced positive response for VHL-associated kidney cancer
Results from a phase II international trial led by researchers [...]
Lenvatinib plus pembrolizumab shows promise in solid tumours
The combination of lenvatinib plus pembrolizumab has shown promise in [...]
